Montelair tablets are a modern and effective oral medication that plays an important role in the long-term management of respiratory diseases involving inflammation, such as asthma and allergic rhinitis. Montelukast contains the active ingredient montelukast at a concentration of 5 mg per tablet. Montelukast belongs to a class of medications known as leukotriene receptor antagonists (LRAs). They work by blocking the action of leukotrienes, powerful chemicals produced by the body that play a key role in causing inflammation, bronchial constriction, and increased mucus production-processes that contribute to the symptoms of asthma and allergic rhinitis. Montelair is a valuable treatment option for controlling asthma, improving lung function, reducing the need for fast-acting decongestants, and providing effective relief from the symptoms of seasonal and perennial allergic rhinitis.
The active ingredient in Montelair tablets
The therapeutic efficacy of Montelair tablets depends primarily on the following active ingredient:
Montelukast: 5 mg per tablet. Montelukast is also available in other strengths suitable for different age groups, such as 4 mg chewable tablets for children and 10 mg tablets for adults and adolescents. Montelukast selectively blocks leukotriene CysLT1 receptors in the respiratory tract.
Mechanism of Action of Montelair Tablets
Montelair works by affecting the leukotriene pathway in the body.
Its primary mechanism of action is:
Preventing the binding of leukotrienes to their receptors: Leukotrienes such as LTC4, LTD4, and LTE4 are produced by certain cells in the body in response to irritants and allergies. These leukotrienes bind to specific CysLT1 receptors located on the surface of smooth muscle cells in the bronchial tubes and other cells involved in inflammation in the respiratory tract and nose. Binding of leukotriene receptors leads to bronchial constriction, increased mucus secretion, increased vascular permeability, and recruitment of inflammatory cells.
Blocking leukotriene receptors: Montelukast binds strongly to leukotriene receptors (CysLT1) and prevents leukotrienes from binding to them and activating them. This prevents the harmful effects of leukotrienes in the respiratory and nasal tracts.
Reducing inflammation and bronchodilation: By blocking leukotriene receptors, Montelukast helps reduce inflammation in the bronchi and nose and causes bronchial dilation, facilitating breathing. It also reduces mucus secretion and congestion. Montelukast tablets are used to treat a range of respiratory and allergic conditions, including:
Control of chronic asthma and prevention of asthma attacks: It is used as maintenance treatment for asthma in adults and children, and as an add-on to inhaled corticosteroids, particularly in patients with nighttime asthma symptoms or exercise-induced asthma. It is not a substitute for rescue medications for the treatment of acute attacks.
Prevention of exercise-induced bronchoconstriction: It can be used to prevent or reduce the severity of asthma symptoms that occur during or after exercise.
Relief of symptoms of seasonal and perennial allergic rhinitis: including recurrent sneezing, runny nose, itchy nose, nasal congestion, and stuffy nose caused by allergens such as pollen, dust mites, and animal dander.